$64.55
0.73% today
Nasdaq, Nov 12, 07:18 pm CET
ISIN
US76155X1000
Symbol
RVMD

Revolution Medicines Inc Stock price

$64.08
+15.33 31.45% 1M
+22.20 53.01% 6M
+20.34 46.50% YTD
+3.48 5.74% 1Y
+41.91 189.04% 3Y
+28.32 79.19% 5Y
+35.18 121.73% 10Y
+35.18 121.73% 20Y
Nasdaq, Closing price Tue, Nov 11 2025
+1.35 2.15%
ISIN
US76155X1000
Symbol
RVMD
Industry

Key metrics

Basic
Market capitalization
$12.4b
Enterprise Value
$10.7b
Net debt
positive
Cash
$1.9b
Shares outstanding
189.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 3,114.1
EV/Sales
- | 2,693.0
EV/FCF
negative
P/B
7.8
Financial Health
Equity Ratio
88.5%
Return on Equity
-26.5%
ROCE
-26.5%
ROIC
-223.7%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $4.0m
EBITDA
$-526.1m | $-1.1b
EBIT
$-531.6m | $-1.1b
Net Income
$-499.8m | $-1.0b
Free Cash Flow
$-777.1m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
18.6% | -56.2%
EBIT
19.0% | -59.9%
Net Income
11.9% | -73.0%
Free Cash Flow
-41.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -26,772.6%
EBIT
-
Net
- | -26,093.4%
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
$-4.1
Short interest
11.0%
Employees
534
Rev per Employee
$0.0
Show more

Is Revolution Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Revolution Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Revolution Medicines Inc forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Revolution Medicines Inc forecast:

Buy
96%
Hold
4%

Financial data from Revolution Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 81 81
20% 20%
-
- Research and Development Expense 451 451
19% 19%
-
-526 -526
19% 19%
-
- Depreciation and Amortization 5.51 5.51
45% 45%
-
EBIT (Operating Income) EBIT -532 -532
19% 19%
-
Net Profit -500 -500
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Revolution Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Revolution Medicines Inc Stock News

Neutral
Seeking Alpha
one day ago
Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So we'll get started r...
Neutral
Seeking Alpha
7 days ago
Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Alan Bart Sandler - Chief Development Officer Anthony Mancini Stephen Kelsey - President of Research & Development Confer...
Neutral
GlobeNewsWire
7 days ago
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line m...
More Revolution Medicines Inc News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.

Head office United States
CEO Mark Goldsmith
Employees 534
Founded 2004
Website www.revmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today